<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2019.92015</article-id><article-id pub-id-type="publisher-id">MD-31067</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20190200000_38922648.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清胱抑素C与冠心病后慢性心衰关系的研究进展
  Progress on the Relationship between Serum Cystatin C Level and Chronic Heart Failure after Coronary Heart Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>琴琴</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>延宏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>03</day><month>06</month><year>2019</year></pub-date><volume>09</volume><issue>02</issue><fpage>77</fpage><lpage>80</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  血清胱抑素C (serum cystatin C, SCysC)又名γ2痕迹碱性蛋白或后γ球蛋白，是一种低分子量的非糖基碱性分泌性蛋白，属半胱氨酸蛋白酶抑制剂家族。在病理状态下，尤其是在冠心病后慢性心衰(Chronic heart failure, CHF)后，SCysC表达水平会升高，提示SCysC在其病理生理过程中有重要作用。近年研究证实，冠心病后CHD患者SCysC水平高，且SCysC水平与冠心病后CHF的严重程度密切相关。本文主要对SCysC的分子结构与功能及其与冠心病后CHF的关系进行综述，为临床诊断和治疗CHF提供参考意义。
   Serum cystatin C (SCysC), also known as 2-trace alkaline protein or post-gamma globulin, is a low molecular weight non-glycosylated alkaline secreted protein, belonging to the family of cysteine protease inhibitors. In the pathological state, especially after chronic heart failure (CHF) after coronary heart disease, the expression level of SCysC will increase, suggesting that SCysC plays an important role in its physiological process. Recent studies have confirmed that CHD patients have high SCysC levels, and SCysC levels are closely related to the severity of CHF after CHD. The paper mainly reviews the molecular structure and the function and its relationship with CHF after coro-nary heart disease, to provide reference for clinical diagnosis and treatment of CHF. 
 
</p></abstract><kwd-group><kwd>冠心病后慢性心衰，血清胱抑素C，综述, Chronic Heart Failure after Coronary Heart Disease</kwd><kwd> Serum Cystatin C</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>血清胱抑素C与冠心病后慢性心衰关系的研究进展<sup> </sup></title><p>杨琴琴，罗延宏</p><p>延安大学附属医院，陕西 延安</p><p><img src="//html.hanspub.org/file/9-2170219x1_hanspub.png" /></p><p>收稿日期：2019年6月6日；录用日期：2019年6月21日；发布日期：2019年6月28日</p><disp-formula id="hanspub.31067-formula153"><graphic xlink:href="//html.hanspub.org/file/9-2170219x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>血清胱抑素C (serum cystatin C, SCysC)又名γ<sup>2</sup>痕迹碱性蛋白或后γ球蛋白，是一种低分子量的非糖基碱性分泌性蛋白，属半胱氨酸蛋白酶抑制剂家族。在病理状态下，尤其是在冠心病后慢性心衰(Chronic heart failure, CHF)后，SCysC表达水平会升高，提示SCysC在其病理生理过程中有重要作用。近年研究证实，冠心病后CHD患者SCysC水平高，且SCysC水平与冠心病后CHF的严重程度密切相关。本文主要对SCysC的分子结构与功能及其与冠心病后CHF的关系进行综述，为临床诊断和治疗CHF提供参考意义。</p><p>关键词 :冠心病后慢性心衰，血清胱抑素C，综述</p><disp-formula id="hanspub.31067-formula154"><graphic xlink:href="//html.hanspub.org/file/9-2170219x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-2170219x7_hanspub.png" /> <img src="//html.hanspub.org/file/9-2170219x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>慢性心力衰竭(CHF)是大多数心血管疾病的最终归宿及最主要的死亡原因。近年来其发病率持续增长，有临床症状患者的5年存活率与恶性肿瘤相仿 [<xref ref-type="bibr" rid="hanspub.31067-ref1">1</xref>] 。早期发现并处理CHF相当重要。《2018年中国心力衰竭诊断和治疗指南》流行病学显示 [<xref ref-type="bibr" rid="hanspub.31067-ref2">2</xref>] CHF病因以冠心病居首。各年龄段心衰病死率均高于同期其他心血管病。有研究表明 [<xref ref-type="bibr" rid="hanspub.31067-ref3">3</xref>] 血清CysC可抑制内源性半胱氨酸蛋白酶活性，参与细胞外基质产生和降解间的动态平衡，降低心肌顺应性，参与心室重构，导致心功能恶化。国外研究显示 [<xref ref-type="bibr" rid="hanspub.31067-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref8">8</xref>] 血清CysC可通过对血管内皮细胞功能、血管平滑肌细胞、凝血及脂质过氧化的影响对心肌及内膜产生毒性作用，并参与炎症反应，抑制酶及激素前体的活性，与左室肥厚及舒张功能有关。近年国外研究表明SCysC参与心室重构，而国内少见报道 [<xref ref-type="bibr" rid="hanspub.31067-ref9">9</xref>] 。本文主要对SCysC的分子结构与功能及其与冠心病后CHF的关系进行综述，为临床诊治CHF及其预后提供参考。</p></sec><sec id="s4"><title>2. SCysC的分子结构与功能</title><p>SCysC由122个氨基酸组成，相对分子量为13 KD，在机体内广泛分布，生理作用为使细胞膜免受内源性或者外源性的蛋白酶水解，在动脉壁溶解平衡与抗蛋白溶解活性平衡中发挥重要作用 [<xref ref-type="bibr" rid="hanspub.31067-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref11">11</xref>] 。许多研究证实SCysC为评价肾功能的理想内源性标志物，与肌酐相比更敏感准确 [<xref ref-type="bibr" rid="hanspub.31067-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref13">13</xref>] 。近年研究发现，肾功正常的患者研究也存在SCysC水平升高 [<xref ref-type="bibr" rid="hanspub.31067-ref14">14</xref>] 。国外相关研究表明其参与许多心管系统疾病的病理生理过程 [<xref ref-type="bibr" rid="hanspub.31067-ref15">15</xref>] 。</p></sec><sec id="s5"><title>3. SCysC与冠心病后慢性心衰的关系</title><p>冠心病后CHF的实质是心肌细胞损伤、心肌细胞凋亡及细胞外基质的改变致使心室重构，最后导致CHF [<xref ref-type="bibr" rid="hanspub.31067-ref16">16</xref>] 。以往人们关注的焦点总是心肌细胞的改变，现人们逐渐认识到了心肌细胞外基质改变在CHF发生发展中的作用。细胞外基质重构的发生是心肌胶原合成与降解失衡的结果 [<xref ref-type="bibr" rid="hanspub.31067-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref18">18</xref>] 。有研究表明 [<xref ref-type="bibr" rid="hanspub.31067-ref15">15</xref>] SCys-C可抑制内源性半胱氨酸蛋白酶活性，参与细胞外基质产生和降解间的动态平衡，降低心肌顺应性，参与心室重构，导致心功能恶化。国外研究显示 [<xref ref-type="bibr" rid="hanspub.31067-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.31067-ref8">8</xref>] SCys-C可通过对血管内皮细胞功能、血管平滑肌细胞、凝血及脂质过氧化的影响对心肌及内膜产生毒性作用，并参与炎症反应，抑制酶及激素前体的活性，与左室肥厚及舒张功能有关。相关研究表明SCysC水平与冠心病后心衰患者心功能NYHA分级呈正相关 [<xref ref-type="bibr" rid="hanspub.31067-ref19">19</xref>] 。此外，有学者研究表明高水平SCysC可增加冠心病的全因死亡率、心血管事件及心衰的发生率 [<xref ref-type="bibr" rid="hanspub.31067-ref20">20</xref>] 。SCysC可作为冠心病后慢性心衰的患者近期心血管事件及死亡的独立预测因子与近期的预后有密切的关系 [<xref ref-type="bibr" rid="hanspub.31067-ref21">21</xref>] 。</p></sec><sec id="s6"><title>4. 小结与展望</title><p>冠心病后慢性心力衰竭是心血管疾病的终末期表现及最主要的死因。近年来，CHF患病率逐年升高，严重威胁患者的生活质量及健康寿命，SCysC可作为临床诊断及判断冠心病后CHF严重程度的实验室指标 [<xref ref-type="bibr" rid="hanspub.31067-ref20">20</xref>] 。早期根据SCysC水平早期进行危险分层，尽早给予合理的治疗措施可改善预后。但SCysC与冠心病后CHF相关性的更确切机制尚待进一步深入研究。</p></sec><sec id="s7"><title>文章引用</title><p>杨琴琴,罗延宏. 血清胱抑素C与冠心病后慢性心衰关系的研究进展Progress on the Relationship between Serum Cystatin C Level and Chronic Heart Failure after Coronary Heart Disease[J]. 医学诊断, 2019, 09(02): 77-80. https://doi.org/10.12677/MD.2019.92015</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.31067-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, R., Ma, P., Xiong, A., et al. (2017) Protective Effects of Low-Dose Rosuvastatin on Isoproterenol-Induced Chronic Heart Failure in Rats by Regulation of DDAH-ADMA-NO Pathway. Cardiovascular Therapeutics, 35, e12241. &lt;br&gt;https://doi.org/10.1111/1755-5922.12241</mixed-citation></ref><ref id="hanspub.31067-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tendera, M. (2005) Epidemiology, Treatment, and Guidelines for the Treatment of Heart Failure in Europe. European Heart Journal Supplements, 7, J5-J9. &lt;br&gt; https://doi.org/10.1093/eurheartj/sui056</mixed-citation></ref><ref id="hanspub.31067-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">吕国伟. 高血压患者血清胱抑素C与冠心病的关系[D]: [硕士学位论文]. 郑州: 郑州大学, 2013.</mixed-citation></ref><ref id="hanspub.31067-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Lassus, J. and Harjola, V.P. (2012) Cystatin C: A Step forward in Assessing Kidney Function and Cardiovascular Risk. Heart Failure Reviews, 17, 251-261. &lt;br&gt;https://doi.org/10.1007/s10741-011-9242-6</mixed-citation></ref><ref id="hanspub.31067-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Deo, R., Fyr, C.L., Fried, L.F., et al. (2008) Kidney Dysfunction and Fatal Cardiovascular Disease—An Association Independent of Atheroselemtic (Health ABC) Study. American Heart Journal, 155, 62-68.&lt;br&gt;https://doi.org/10.1016/j.ahj.2007.08.012</mixed-citation></ref><ref id="hanspub.31067-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Barka, T. and vander Noen, H. (1993) Expression of the Eysteine Proteinase Inhibitor Cystatin C Gene in Rat Heart: Use of Digoxigenin-Labeled Probes Generated by Polymerase Chain reaction Directly for in Situ and Northern Blot Hybridizations. Journal of Histochemistry &amp; Cytochemistry, 41, 1863-1867. &lt;br&gt;https://doi.org/10.1177/41.12.8245434</mixed-citation></ref><ref id="hanspub.31067-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ix, J.H., Shlipak, M.G., Cheaow, G.M., et al. (2006) Cystatin C, Left Ventricular Hypertrophy and Diastolic Dysfunction: Data from the Heart and Soul Study. Journal of Cardiac Failure, 12, 601-607.&lt;br&gt;https://doi.org/10.1016/j.cardfail.2006.07.005</mixed-citation></ref><ref id="hanspub.31067-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Patel, P.C., Ayers, C.R., Murphy, S.A., et al. (2009) Association of Cystatin C with Left Ventricular Structure and Function: The Dallas Heart Study. Circulation: Heart Failure, 2, 98-104. &lt;br&gt;https://doi.org/10.1161/CIRCHEARTFAILURE.108.807271</mixed-citation></ref><ref id="hanspub.31067-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lok, D.J., Lok, S.I., Badings, E., et al. (2013) Galectin-3 Is an Independent Marker for Ventricular Remodeling and Mortality in Patients with Chronic Heart Failure. Clinical Research in Cardiology, 102, 103-110.&lt;br&gt;https://doi.org/10.1007/s00392-012-0500-y</mixed-citation></ref><ref id="hanspub.31067-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">刘巍, 郑蕊. 血胱抑素测定在临床诊断中的应用[J]. 中国民康医学, 2009, 21(18): 2291-2291.</mixed-citation></ref><ref id="hanspub.31067-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">刘海燕, 李伟娜, 肖波, 等. 胱抑素C临床检验及在肾脏疾病应用中的研究进展[J]. 河北医药, 2015, 37(21): 3311-3315.</mixed-citation></ref><ref id="hanspub.31067-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Elshafey, E.M., Elnagar, G.F., Selim, M.F., et al. (2009) Is Serum Cystatin C an Accurate Endogenous Marker of Glomerular Filteration Rate for Detection of Early Renal Impairment in Patients with Type 2 Diabetes Mellitus? Renal Failure, 31, 355-359. &lt;br&gt; https://doi.org/10.1080/08860220902839089</mixed-citation></ref><ref id="hanspub.31067-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Christensson, A., Ekberg, J., Grubb, A., et al. (2003) Serum Cystatin C Is a More Sensitive and More Accurate Marker of Glomerular Filtration Rate than Enzymatic Measurements of Creatinine in Renal Transplantation. Nephron Physiology, 94, 19-27. &lt;br&gt;https://doi.org/10.1159/000071287</mixed-citation></ref><ref id="hanspub.31067-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Perkins, B.A., Nelson, R.G., Ostrander, B.E.P., et al. (2005) Detection of Renal Function Decline in Patients with Diabetes and Normal or Elevated GFR by Serial Measurements of Serum Cystatin C Concentration: Results of a 4-Year Follow-Up Study. Journal of the American Society of Nephrology, 16, 1404-1412. &lt;br&gt;https://doi.org/10.1681/ASN.2004100854</mixed-citation></ref><ref id="hanspub.31067-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Su, X., Zhang, W., et al. (2015) Correlation between Serum Cystatin C Level and Elderly Hypertensive Patients Combined Coronary Heart Disease. International Journal of Clinical &amp; Experimental Medicine, 8, 6287-6290.</mixed-citation></ref><ref id="hanspub.31067-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Petrovic, D. (2004) Cytopathological Basis of Heart Failure-Cardiomyocyte Apoptosis, Interstitial Fibrosis and Inflammatory Cell Response. Folia Biologica, 50, 58-62.</mixed-citation></ref><ref id="hanspub.31067-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Jugdutt, B.I. (2003) Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways. Current Drug Targets—Cardiovascular &amp; Hematological Disorders, 3, 1-30.&lt;br&gt;https://doi.org/10.2174/1568006033337276</mixed-citation></ref><ref id="hanspub.31067-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Medvedev, N.V. and Gorshunova, N.K. (2014) Apoptosis and Interstitial Fibrosis in Remodeling of the Myocardium in Elderly Patients with Arterial Hypertension. Advances in Gerontology, 4, 46-50. &lt;br&gt;https://doi.org/10.1134/S2079057014010056</mixed-citation></ref><ref id="hanspub.31067-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Shimoyama, N., Maeda, T., Inoue, T., Niwa, H. and Saikawa, T. (1993) Serum Thyroid Hormone Levels Correlate with Cardiac Function and Ventricular Tachyarrhythmia in Patients with Chronic Heart Failure. Journal of Cardiology, 23, 205-213.</mixed-citation></ref><ref id="hanspub.31067-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ix, J.H., Shlipak, M.G., Chertow, G.M. and Whooley, M.A. (2007) Association of Cystatin C with Mortality, Cardiovascular Events, and Incident Heart Failure among Persons with Coronary Heart Disease: Data From the Heart and Soul Study. Circulation, 115, 173-179. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.106.644286</mixed-citation></ref><ref id="hanspub.31067-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Arimoto, T., Takeishi, Y., Niizeki, T., et al. (2005) Cystatin C, a Novel Measure of Renal Function, Is an Independent Predictor of Cardiac Events in Patients with Heart Failure. Journal of Cardiac Failure, 11, 595-601.&lt;br&gt;https://doi.org/10.1016/j.cardfail.2005.06.001</mixed-citation></ref></ref-list></back></article>